The Graft-Versus-Lymphoma Effect in Diffuse Large B-Cell Lymphoma

Christina Smith(University of Michigan–Ann Arbor), Tracey Churay(University of Michigan–Ann Arbor), Holly A. Justman(University of Michigan–Ann Arbor), Jessica Yu(University of Michigan–Ann Arbor), Attaphol Pawarode(University of Michigan–Ann Arbor), David A. Hanauer(University of Michigan–Ann Arbor), John Magenau(University of Michigan–Ann Arbor), Steven C. Goldstein(University of Pennsylvania), Mary Riwes(University of Michigan–Ann Arbor), Brian Parkin(University of Michigan–Ann Arbor), John E. Levine(University of Michigan–Ann Arbor), Daniel R. Couriel(University of Michigan–Ann Arbor)
Biology of Blood and Marrow Transplantation
January 22, 2015
10.1016/j.bbmt.2014.11.312
Cited by 0Open Access
Full Text

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma in the adult population, representing 25-35% of new non-Hodgkin lymphoma cases each year (Cultrera & Dalia, 2012). Autologous hematopoietic stem cell transplant (HSCT) is the standard of care after relapse following conventional treatment, with a curative potential of 25-50%, but recurrences are common. Allogeneic HSCT represents a salvage option through the benefit of graft-versus-lymphoma effect. The role of allogeneic HSCT in patients with advanced DLBCL still remains to be defined.

Related Papers

No related papers found

Powered by citation graph analysis